Menu
Sophia Genetics, global leader in Data-Driven Medicine, and Devyser, pioneer in diagnostic kits for complex DNA testing, announce today the signing of a new partnership to simplify the adoption of Next-Generation DNA Sequencing (NGS) for routine diagnostic laboratories. Under the terms of the agreement, Sophia Genetics’ advanced analytical platform, Sophia DDM®, will support Devyser’s NGS diagnostic kits for hereditary breast cancer (Devyser BRCA) and cystic fibrosis (Devyser CFTR).
Ulf Klangby, CEO and co-founder of Devyser, says, “We are very excited to offer NGS technology that has the capacity to revolutionize genetic testing. This solution will relieve laboratories from the burden of labor-intensive and complex workflows so that they can really focus on diagnostics. Our partnership will help continue to reduce the diagnostic turnaround time from days to hours, enabling laboratories to significantly improve their efficiency and cut costs.”
Jurgi Camblong, CEO and founder of Sophia Genetics, comments, “We are very pleased to broaden the choice of NGS kits supported by Sophia DDM®. Our fast-growing clinical genomics community will be able to leverage Devyser’s reliable and easy-to-use products to obtain clinical grade results on Sophia DDM®. This partnership continues to help laboratories unlock the power of NGS with record-low turnaround time, improving both diagnostics and treatment options for patients.”
Sophia Genetics’ and Devyser’s joint effort will immediately be launched worldwide to help routine diagnostic laboratories transition to NGS and obtain improved throughput, reduced hands-on time and trusted results. The solutions will be available through Devyser’s distribution network and to the more than 170 member hospitals of the Sophia DDM® clinical genomics community.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us at [email protected] to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.
